Company profile
CytoMed Therapeutics Ltd
NASDAQ:GDTCBiotechnology: Pharmaceutical Preparations
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05302037 | phase1 | recruiting | 2024-11-19 | 2025-11-01 | CytoMed Therapeutics Pte Ltd | Allogeneic NKG2DL-targeting CAR γδ T Cells (CTM-N2D) in Advanced Cancers (ANGELICA) |
| NCT04107142 | phase1 | unknown | 2019-12-01 | 2020-09-01 | CytoMed Therapeutics Pte Ltd | Haplo / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells for Relapsed or Refractory Solid Tumour |
FDA applications (0)
No records yet.